The stock price of IN8bio Inc. (NASDAQ: INAB) has surged by 7.80 when compared to previous closing price of 0.96, but the company has seen a 4.89% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-08-15 that NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17, 2023 at 2:00 pm ET.
Is It Worth Investing in IN8bio Inc. (NASDAQ: INAB) Right Now?
The 36-month beta value for INAB is also noteworthy at -0.20. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price estimated by analysts for INAB is $13.00, which is $11.97 above than the current price. The public float for INAB is 24.21M, and at present, short sellers hold a 0.36% of that float. The average trading volume of INAB on September 20, 2023 was 142.01K shares.
INAB’s Market Performance
The stock of IN8bio Inc. (INAB) has seen a 4.89% increase in the past week, with a -10.43% drop in the past month, and a -47.98% fall in the past quarter. The volatility ratio for the week is 9.66%, and the volatility levels for the past 30 days are at 7.86% for INAB. The simple moving average for the past 20 days is 0.35% for INAB’s stock, with a -42.55% simple moving average for the past 200 days.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with H.C. Wainwright repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to H.C. Wainwright is $14 based on the research report published on August 30, 2022 of the previous year 2022.
INAB Trading at -16.87% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.92% of loss for the given period.
Volatility was left at 7.86%, however, over the last 30 days, the volatility rate increased by 9.66%, as shares sank -8.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.46% lower at present.
During the last 5 trading sessions, INAB rose by +4.89%, which changed the moving average for the period of 200-days by -40.80% in comparison to the 20-day moving average, which settled at $1.0214. In addition, IN8bio Inc. saw -55.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INAB starting from Graff Jeremy R., who purchase 2,500 shares at the price of $0.95 back on Sep 13. After this action, Graff Jeremy R. now owns 2,500 shares of IN8bio Inc., valued at $2,375 using the latest closing price.
McCall Patrick, the Chief Financial Officer of IN8bio Inc., purchase 1,000 shares at $1.03 during a trade that took place back on Aug 25, which means that McCall Patrick is holding 6,263 shares at $1,030 based on the most recent closing price.
Stock Fundamentals for INAB
The total capital return value is set at -82.43, while invested capital returns managed to touch -84.90. Equity return is now at value -134.00, with -96.80 for asset returns.
Based on IN8bio Inc. (INAB), the company’s capital structure generated 25.84 points at debt to equity in total, while total debt to capital is 20.53. Total debt to assets is 17.78, with long-term debt to equity ratio resting at 19.73. Finally, the long-term debt to capital ratio is 15.68.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.82.
Conclusion
In summary, IN8bio Inc. (INAB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
